Qiagen (QGEN) AI Stock Analysis

• Market Cap: $9.96B
• Dividend Yield: 2.72%
• Average Volume (3M): 1.44M
• Price to Earnings (P/E): 26.9
• Beta (1Y): 0.72
• Revenue Growth: 5.15%
• EPS Growth: 412.41%
• Country: US
• Employees: 5,700
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.60
• Shares Outstanding: 216,556,000
• 10 Day Avg. Volume: 1,729,348
• 30 Day Avg. Volume: 1,441,407
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 5.38
• Enterprise Value/Gross Profit: 8.54
• Enterprise Value/Ebitda: 15.35
• 1Y Price Target: $51.88
• Price Target Upside: 12.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14

• Rating: 70 Outperform
• Price Target: $52.00 ▲(12.90% Upside)

Qiagen's overall stock score is driven by strong earnings performance and positive guidance, which are offset by technical weaknesses and a high valuation. The company's stable financial performance and strategic growth initiatives support its position, but challenges in specific regions and product lines remain.

Positive Factors

Revenue Growth

Qiagen's consistent revenue growth highlights its strong market position and effective sales strategies, ensuring long-term business stability.

Growth in Key Products

Significant growth in key products like QIAstat and QuantiFERON demonstrates strong demand and successful strategic initiatives, supporting future expansion.

Improved Profitability

Improved profitability through higher operating margins indicates effective cost management and operational efficiency, enhancing long-term financial health.

Negative Factors

Decline in Asia Pacific Region

A decline in the Asia Pacific region could indicate regional challenges and impact overall growth, necessitating strategic adjustments to regain momentum.

Flat Sample Technologies Sales

Flat sales in sample technologies suggest stagnation in a key product line, potentially limiting growth unless addressed with innovation or market expansion.

Cash Flow Conversion Challenges

Challenges in converting profits into free cash flow could affect liquidity and investment capacity, impacting long-term strategic initiatives.

Qiagen Business Overview & Revenue Model

Company Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

How the Company Makes Money

Qiagen generates revenue primarily through the sale of its molecular testing products and services, which fall into several key categories: sample technologies, assay technologies, and bioinformatics. The company benefits from a diversified revenue model, with substantial income derived from both consumables (such as kits and reagents) and instruments used in laboratories. Additionally, Qiagen has established significant partnerships with various pharmaceutical and biotechnology companies, which can lead to collaborative development of diagnostic tests and expand their market reach. The growing demand for personalized medicine and advancements in genetic testing further contribute to Qiagen's earnings, as they cater to the increasing need for precision diagnostics in healthcare.

Qiagen Financial Statement Overview

Summary

Qiagen demonstrates stable financial performance with consistent revenue and operational efficiency. Improvements in leverage and cost management are noted, but challenges remain in profitability growth and cash flow conversion.

Income Statement

Qiagen's income statement shows a stable revenue base with a slight growth in TTM (Trailing-Twelve-Months). The gross profit margin has decreased from previous years, indicating potential cost pressures. However, the net profit margin has improved slightly in the TTM, suggesting better cost management. The EBIT and EBITDA margins are stable, reflecting consistent operational efficiency.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, which has improved over the years, indicating better leverage management. The return on equity (ROE) is relatively low, suggesting limited profitability from equity investments. The equity ratio is stable, indicating a balanced asset structure.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth in the TTM, which could be a concern for future liquidity. The operating cash flow to net income ratio is strong, indicating good cash generation from operations. However, the free cash flow to net income ratio has decreased, suggesting potential challenges in converting profits into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.04B	1.98B	1.97B	2.14B	2.25B	1.87B
Gross Profit	1.28B	967.35M	1.23B	1.38B	1.45B	1.23B
EBITDA	715.13M	368.26M	688.55M	779.36M	895.24M	715.80M
Net Income	373.39M	83.59M	341.30M	423.21M	512.60M	359.19M
Balance Sheet
Total Assets	5.82B	5.69B	6.12B	6.29B	6.15B	5.87B
Cash, Cash Equivalents and Short-Term Investments	953.82M	1.15B	1.06B	1.42B	1.07B	715.23M
Total Debt	1.44B	1.51B	1.61B	1.96B	2.04B	2.03B
Total Liabilities	2.32B	2.12B	2.31B	2.82B	3.05B	3.07B
Stockholders Equity	3.51B	3.57B	3.81B	3.47B	3.10B	2.80B
Cash Flow
Free Cash Flow	496.32M	506.38M	296.65M	565.93M	432.47M	188.03M
Operating Cash Flow	675.03M	673.55M	459.45M	715.26M	639.00M	492.27M
Investing Cash Flow	-159.74M	-249.23M	-87.66M	-726.76M	-202.43M	-453.29M
Financing Cash Flow	-318.12M	-422.90M	-433.83M	-125.80M	-150.37M	-74.32M

Qiagen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Negative. The current price of 46.06 is below the 20-day moving average (MA) of 47.88, below the 50-day MA of 48.57, and above the 200-day MA of 44.19, indicating a neutral trend. The MACD of -0.62 indicates Positive momentum. The RSI at 37.19 is Neutral, neither overbought nor oversold. The STOCH value of 26.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QGEN.

Qiagen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IQV	79 Outperform	$31.26B	26.63	19.80%	―	3.53%	-10.72%
TMO	78 Outperform	$179.95B	27.58	13.44%	0.34%	2.05%	7.03%
IDXX	77 Outperform	$51.04B	53.10	64.87%	―	6.68%	18.84%
QGEN	70 Outperform	$9.96B	26.93	10.81%	2.72%	5.15%	412.41%
ILMN	62 Neutral	$15.09B	12.44	68.11%	―	-3.32%	―
RVTY	61 Neutral	$9.58B	35.01	3.61%	0.33%	3.33%	32.86%
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%